In localized prostate cancer, does radical prostatectomy improve overall or prostate-cancer mortality compared with observation?
Tumour site
Prostate Cancer
Discipline
Surgical
Clinical setting
Localized Disease
Evidence type
Comparative clinical evidence
Absolute Effect
PIVOT randomized men with localized prostate cancer to radical prostatectomy or observation. Extended follow-up (median follow-up among survivors 18.6 years) found 246/346 men assigned to surgery (68%) and 269/367 assigned to observation (73%) died; HR for all-cause mortality 0.84 (95% CI 0.70–1.00; P=.044). The absolute risk reduction estimate was 5.7 percentage points with a 95% CI crossing zero, so the absolute magnitude remains uncertain.
NNT / NNH: Calculated only when a defensible fixed-time absolute event difference is available. Hazard ratios alone are not converted into NNT.
Clinical interpretation
PIVOT suggests at most a modest long-term mortality difference between surgery and observation, with uncertainty in the absolute risk estimate; treatment should be individualized by modern risk and life expectancy.
Limitations
The trial predates contemporary MRI, active-surveillance protocols and current risk stratification; its observation arm should not be equated directly with modern active surveillance.
In the extended follow-up analysis (median follow-up among survivors 18.6 years), 246/346 men assigned to surgery (68%) and 269/367 assigned to observation (73%) died. The hazard ratio for all-cause mortality was 0.84 (95% CI 0.70–1.00; P=.044); the estimated absolute risk reduction was 5.7 percentage points, but its 95% CI crossed zero (−0.89 to 12 percentage points). Restricted mean survival was 13.6 versus 12.6 years.
The results suggest a modest possible long-term advantage for surgery, with uncertainty around the absolute difference; they do not justify treating surgery as mandatory for every localized prostate cancer patient.
Current-practice context · reviewed 14 October 2026
PIVOT enrolled patients in an earlier diagnostic and treatment era. Modern management separates active surveillance for suitable low-risk disease from watchful waiting in patients with limited life expectancy, and individualizes definitive treatment for intermediate/high-risk disease. Use current risk classification, life expectancy, comorbidity, MRI/biopsy findings and patient preferences; do not translate PIVOT into a universal surgery-versus-no-treatment rule.